UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Delaware 13-2740040 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1301 Municipal Way, Suite 220, Grapevine, TX 76051 (Address of principal executive offices) (Zip Code) (972) 453-7000 (Registrant's telephone number, including area cod ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-39411 Vital Farms, Inc. (Exact name of registrant as specified in its charter) Delaware 27-0496985 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

Exhibit 99.1 Thryv Achieves SaaS Revenue Growth of 34% in Full Year 2025, Shifts Focus to AI-Enabled "Market, Sell, Grow" Platform to Empower SMBs DALLAS, February 26, 2026 – Thryv Holdings, Inc. (NASDAQ:THRY) ("Thryv" or the "Company"), the provider of Thryv®, the leading small business marketing and sales software platform, reported an increase in SaaS revenue of 14% year-over-year in the fourth quarter of 2025 and grew 34% year-over-year for the full year 2025. Fourth Quarter Financial 2025 Highlights: F ...

Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results BRISBANE, Calif., February 26, 2026 – Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical- stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the full year ended December 31, 2025. "In 2025, Vera Therapeutics delivered on several key milestones as ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14875 FTI CONSULTING, INC. (Exact name of registrant as specified in its charter) Maryland 52-1261113 (State or other jurisdiction of incorporat ...

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors with three additional clinical trials across the portfolio expected to initiate in 2026 Completed $185 million private placement, supporting several key clinical data readouts beginning in Q1 2027 and providing expected cash runway into 2028 Waltham, Mass., February 26, 2026 – Crescent Biopharma, Inc. ("Cresc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36177 Crescent Biopharma, Inc. (Exact name of registrant as specified in its charter) Cayman Islands 06-1686563 (St ...

Financial Performance - Fourth quarter net investment income was $0.44 per share, with a net increase in net assets resulting from operations of $0.32 per share[7]. - Total investment income for 2025 was $207,858, down from $224,040 in 2024, representing a decrease of about 7.24%[29]. - Net investment income for 2025 was $93,338, compared to $122,388 in 2024, a decrease of approximately 23.77%[30]. - Net increase in net assets resulting from operations for 2025 was $65,614, down from $116,323 in 2024, a decrease of approximately 43.59%[30]. Portfolio Investments - The fair value of the company's portfolio investments remained stable at $2.0 billion, with an increase in the number of portfolio companies from 213 to 227[6]. - The company funded $80.4 million in portfolio investments during the fourth quarter, compared to $36.3 million in the previous quarter[11]. - New gross commitments at par for 2025 were $302,546, significantly lower than $955,309 in 2024, a decrease of about 68.32%[32]. - Net funded investment activity for 2025 was $(105,462), a substantial decline from $433,617 in 2024[32]. - The number of new portfolio companies increased to 58 in 2025 from 68 in 2024, a decrease of about 14.71%[32]. Shareholder Value - The company declared a first quarter distribution of $0.40 per share, consisting of a regular distribution of $0.36 per share and a supplemental distribution of $0.04 per share[4]. - The board authorized a $50 million share repurchase program to enhance shareholder value[5]. - The company paid a fourth quarter regular distribution of $0.45 per share, reflecting a 10.1% total annualized distribution yield based on the fourth quarter NAV per share[7]. Debt and Liabilities - As of December 31, 2025, the company's debt to equity ratio was 1.27x, compared to 1.25x at the end of the previous quarter[18]. - Total liabilities increased slightly from $1,173,405 in 2024 to $1,179,289 in 2025, an increase of about 0.50%[26]. Asset Changes - Total assets decreased from $2,143,725 in 2024 to $2,054,469 in 2025, a decline of approximately 4.15%[26]. - Total net assets decreased from $970,320 in 2024 to $875,180 in 2025, a decline of approximately 9.81%[27]. Investment Losses - The company recorded a net realized loss on investments of $(6.0) million for the full year, an improvement from a net realized loss of $(13.2) million in the previous year[16]. - The company experienced a net change in unrealized loss of $(21.6) million for the full year, compared to a net change in unrealized gain of $7.3 million in the previous year[16]. Investment Yields - The weighted average yield of debt and income-producing investments decreased to 9.48% from 10.33% year-over-year[12]. - The weighted average annual interest rate on new debt investments at par decreased to 9.21% in 2025 from 10.11% in 2024[32].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended31 December 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...